<DOC>
	<DOCNO>NCT02569255</DOCNO>
	<brief_summary>Use new oral anticoagulant ( NOAC ) patient catheter base pulmonary vein isolation ( PVI ) still controversial . Experience report consecutive patient ablate PVI atrial fibrillation treat dabigatran , rivaroxaban , apixaban Nov 2011 Dec 2014 . Patients follow 3 month ablation . All complication possible related use NOAC register .</brief_summary>
	<brief_title>Safe Use New Oral Anticoagulants Ablation Atrial Fibrillation</brief_title>
	<detailed_description>Use new oral anticoagulant ( NOAC ) patient radiofrequency ablation pulmonary vein isolation ( PVI ) still controversial . Experience report consecutive patient ablate PVI atrial fibrillation treat dabigatran , rivaroxaban , apixaban Nov 2011 Dec 2014 . Patients pause NOAC treatment 24 hour ablation . Patients routinely follow 3 month standard formular focus possible adverse event ( major bleed complication thromboembolic event ) NOAC treatment . Adverse event relate use NOAC register treatment 3 month follow-up .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Symptomatic atrial fibrillation despite pharmacological treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>